These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 30396186)

  • 21. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial.
    Grob JJ; Amonkar MM; Karaszewska B; Schachter J; Dummer R; Mackiewicz A; Stroyakovskiy D; Drucis K; Grange F; Chiarion-Sileni V; Rutkowski P; Lichinitser M; Levchenko E; Wolter P; Hauschild A; Long GV; Nathan P; Ribas A; Flaherty K; Sun P; Legos JJ; McDowell DO; Mookerjee B; Schadendorf D; Robert C
    Lancet Oncol; 2015 Oct; 16(13):1389-98. PubMed ID: 26433819
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Melanoma with BRAF Mutation in Circulating Cell-free DNA despite no Mutation in the Primary Lesion: A Case Report.
    Ashida A; Uhara H; Mikoshiba A; Sakaizawa K; Kumagai N; Koga H; Okuyama R
    Acta Derm Venereol; 2016 Jan; 96(1):128-9. PubMed ID: 26123241
    [No Abstract]   [Full Text] [Related]  

  • 23. Investigation of BRAF mutation analysis with different technical platforms in metastatic melanoma.
    Sener E; Yildirim P; Tan A; Gokoz O; Tezel GG
    Pathol Res Pract; 2017 May; 213(5):522-530. PubMed ID: 28216139
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Metastatic Malignant Melanoma With Complete Loss of Differentiation Markers (Undifferentiated/Dedifferentiated Melanoma): Analysis of 14 Patients Emphasizing Phenotypic Plasticity and the Value of Molecular Testing as Surrogate Diagnostic Marker.
    Agaimy A; Specht K; Stoehr R; Lorey T; Märkl B; Niedobitek G; Straub M; Hager T; Reis AC; Schilling B; Schneider-Stock R; Hartmann A; Mentzel T
    Am J Surg Pathol; 2016 Feb; 40(2):181-91. PubMed ID: 26448190
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study.
    Robert C; Dummer R; Gutzmer R; Lorigan P; Kim KB; Nyakas M; Arance A; Liszkay G; Schadendorf D; Cantarini M; Spencer S; Middleton MR
    Lancet Oncol; 2013 Jul; 14(8):733-40. PubMed ID: 23735514
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Treatment of BRAF-mutated metastatic melanoma].
    Boyles TB; Svane IM; Bastholt L; Schmidt H
    Ugeskr Laeger; 2016 Aug; 178(35):. PubMed ID: 27592869
    [TBL] [Abstract][Full Text] [Related]  

  • 27. BRAF V600 mutations and pathological features in Japanese melanoma patients.
    Yamazaki N; Tanaka R; Tsutsumida A; Namikawa K; Eguchi H; Omata W; Oashi K; Ogawa T; Hayashi A; Nakamura N; Tsuta K
    Melanoma Res; 2015 Feb; 25(1):9-14. PubMed ID: 25051202
    [TBL] [Abstract][Full Text] [Related]  

  • 28. BRAF inhibitor activity in V600R metastatic melanoma.
    Klein O; Clements A; Menzies AM; O'Toole S; Kefford RF; Long GV
    Eur J Cancer; 2013 Mar; 49(5):1073-9. PubMed ID: 23237741
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Individualized strategies to target specific mechanisms of disease in malignant melanoma patients displaying unique mutational signatures.
    Curiel-Olmo S; García-Castaño A; Vidal R; Pisonero H; Varela I; León-Castillo A; Trillo E; González-Vela C; García-Diaz N; Almaraz C; Moreno T; Cereceda L; Madureira R; Martinez N; Ortiz-Romero P; Valdizán E; Piris MA; Vaqué JP
    Oncotarget; 2015 Sep; 6(28):25452-65. PubMed ID: 26327537
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Melanoma with in-frame deletion of MAP2K1: a distinct molecular subtype of cutaneous melanoma mutually exclusive from BRAF, NRAS, and NF1 mutations.
    Williams EA; Montesion M; Shah N; Sharaf R; Pavlick DC; Sokol ES; Alexander B; Venstrom J; Elvin JA; Ross JS; Williams KJ; Tse JY; Mochel MC
    Mod Pathol; 2020 Dec; 33(12):2397-2406. PubMed ID: 32483240
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Complete Cytologic Remission of V600E BRAF-Mutant Melanoma-Associated Leptomeningeal Carcinomatosis Upon Treatment With Dabrafenib.
    Wilgenhof S; Neyns B
    J Clin Oncol; 2015 Oct; 33(28):e109-11. PubMed ID: 24733801
    [No Abstract]   [Full Text] [Related]  

  • 32. The association between dermoscopic features and BRAF mutational status in cutaneous melanoma: Significance of the blue-white veil.
    Armengot-Carbó M; Nagore E; García-Casado Z; Botella-Estrada R
    J Am Acad Dermatol; 2018 May; 78(5):920-926.e4. PubMed ID: 29307636
    [TBL] [Abstract][Full Text] [Related]  

  • 33. BRAF VE1 immunoreactivity patterns in epithelioid glioblastomas positive for BRAF V600E mutation.
    Kleinschmidt-DeMasters BK; Aisner DL; Foreman NK
    Am J Surg Pathol; 2015 Apr; 39(4):528-40. PubMed ID: 25581727
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Analytical performance of a real-time PCR-based assay for V600 mutations in the BRAF gene, used as the companion diagnostic test for the novel BRAF inhibitor vemurafenib in metastatic melanoma.
    Halait H; Demartin K; Shah S; Soviero S; Langland R; Cheng S; Hillman G; Wu L; Lawrence HJ
    Diagn Mol Pathol; 2012 Mar; 21(1):1-8. PubMed ID: 22306669
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Molecular characterization of a selected cohort of patients affected by pulmonary metastases of malignant melanoma: Hints from BRAF, NRAS and EGFR evaluation.
    Ulivieri A; Cardillo G; Manente L; Paone G; Mancuso AP; Vigna L; Di Stasio E; Gasbarra R; Girlando S; Leone A
    Oncotarget; 2015 Aug; 6(23):19868-79. PubMed ID: 26305188
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Molecular diagnostics of melanoma fine-needle aspirates: a cytology-histology correlation study.
    Bernacki KD; Betz BL; Weigelin HC; Lao CD; Redman BG; Knoepp SM; Roh MH
    Am J Clin Pathol; 2012 Nov; 138(5):670-7. PubMed ID: 23086767
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A Comparison of Morphologic and Molecular Features of BRAF, ALK, and NTRK1 Fusion Spitzoid Neoplasms.
    Amin SM; Haugh AM; Lee CY; Zhang B; Bubley JA; Merkel EA; Verzì AE; Gerami P
    Am J Surg Pathol; 2017 Apr; 41(4):491-498. PubMed ID: 27776007
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Assessment of clinical parameters associated with mutational status in metastatic malignant melanoma: a single-centre investigation of 141 patients.
    Schlaak M; Bajah A; Podewski T; Kreuzberg N; von Bartenwerffer W; Wardelmann E; Merkelbach-Bruse S; Büttner R; Mauch C; Kurschat P
    Br J Dermatol; 2013 Apr; 168(4):708-16. PubMed ID: 23528057
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Quantification of tumor-derived cell free DNA(cfDNA) by digital PCR (DigPCR) in cerebrospinal fluid of patients with BRAFV600 mutated malignancies.
    Momtaz P; Pentsova E; Abdel-Wahab O; Diamond E; Hyman D; Merghoub T; You D; Gasmi B; Viale A; Chapman PB
    Oncotarget; 2016 Dec; 7(51):85430-85436. PubMed ID: 27863426
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Personalized and targeted mutational analysis of multiple second primary melanomas under kinase inhibitors.
    Donati M; Zelano G; Coppola R; Cinelli E; Verri M; Persichetti P; Perrella E; Devirgiliis V; Calvieri S; Crescenzi A; Panasiti V
    Ital J Dermatol Venerol; 2021 Oct; 156(5):593-598. PubMed ID: 31804055
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.